Artemis Medicare Services Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts more than Nifty Microcap 250 and 5.1 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Artemis Medicare Services reported strong full-year FY26 results with standalone revenue from operations growing 16.1% to ₹1,06,049.17 Lacs from ₹91,326.13 Lacs in FY25. Net profit after tax increased 24% to ₹10,344.15 Lacs versus ₹8,345.78 Lacs, driven by higher international revenues (₹32,268 Lacs, up 27% YoY). EBITDA margin compressed to approximately 20% from ~23.3% in the prior year due to higher operative costs and a ₹307.44 Lacs exceptional charge for new Labour Code implementation. Finance costs declined to ₹2,694.40 Lacs from ₹3,048.26 Lacs. The Board recommended a final dividend of ₹0.45 per share (45%) subject to shareholder approval. The company also issued 17,41,750 equity shares under ESOP and converted ₹33,000 Lacs CCDs into equity in November 2025. Auditors issued an unmodified opinion with no going concern issues.
Artemis Medicare delivered ~24% PAT growth and strong revenue expansion, though margin compression warrants attention. The Labour Code impact is non-recurring. Investors may respond positively to the profit growth and dividend, but the compression in EBITDA margins is a key monitorable.